Home > Drugs A – Z > Basiliximab (By injection)

Basiliximab (By injection)

Prevents organ rejection after a kidney transplant.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Basiliximab belongs to a group of medicines known as immunosuppressive agents. It is used to lower the body's natural immunity in patients who receive kidney transplants. When a patient receives a kidney transplant, the body's white blood cells will try to get rid of (reject) the transplanted kidney. Basiliximab works by preventing the white blood cells from getting rid of the transplanted… Read more
Brand names include
Drug classes About this
Immune Suppressant

What works? Research summarized

Evidence reviews

Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis

OBJECTIVE: To compare efficacy and safety of basiliximab versus antithymocyte globulin (ATG) for induction therapy in kidney transplantation.

Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation

BACKGROUND: Basiliximab is a high-affinity chimeric monoclonal antibody directed against the alpha-chain of the interleukin (IL)-2 receptor. Individual studies have shown that it is highly effective in preventing acute rejection and causes no measurable incremental toxicity. However, incorporation of basiliximab immunoprophylaxis into routine practice depends upon the demonstration of benefit across treatment regimens and quantitation of the treatment effect.

Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation

The study found that tacrolimus maintenance therapy (with azathioprine) and basiliximab induction (with tacrolimus and azathioprine maintenance therapy) were likely to be cost-effective therapies for children and adolescents undergoing renal transplantation. When all immunosuppressive regimens were simultaneously compared using extrapolated adult data, only basiliximab induction therapy with tacrolimus and azathioprine maintenance therapy was cost-effective.

See all (23)

Summaries for consumers

Antibody induction therapy compared with corticosteroids for induction of immunosuppression after liver transplantation

Historically, corticosteroids have been the backbone of immunosuppression after liver transplantation, and corticosteroids are typically started immediately before or during transplantation. However, the use of corticosteroids is associated with several complications such as infection, hepatitis C virus recurrence, diabetes mellitus, hypertension, obesity, osteoporosis, fracture, and reduced quality of life. Hence, corticosteroid avoidance and corticosteroid reduction regimens for liver transplant recipients have been developed.

Interleukin 2 receptor antagonists (IL2Ra) reduce the risk of acute rejection episodes at six and twelve months after kidney transplantation

Acute rejection is a major problem in the early period following kidney transplantation. Immunosuppressive drugs are used to prevent this. IL2Ra, a newer antibody therapy, can be added to a patient's existing immunosuppression to further reduce the risk of rejection. This review found that adding IL2Ra reduced the risk of graft loss or death with a functioning transplant, acute rejection, and early malignancy, but did not improve patient survival. Compared to ATG, another possible antibody option, IL2Ra treatment caused less CMV disease and malignancy and had fewer side effects, but although there was no difference in clinically diagnosed acute rejection, IL2Ra treatment resulted in more biopsy proven rejection at 1 year.

Belatacept for kidney transplant recipients

Kidney transplants can improve the quality and length of life for patients with end‐stage kidney disease (ESKD) compared with chronic dialysis. To prevent a kidney transplant from being rejected by the body, immune‐system suppressing drugs (most commonly a calcineurin inhibitors (CNI)) are used. CNI are associated with high blood pressure, high lipid levels, an increased risk of developing diabetes, and chronic scarring of the kidney transplant. Chronic kidney scarring is the main reason that kidney transplants lose function in people who do not die before their kidney transplant fails. Belatacept might be an alternative immune‐system suppressing drug which prevents rejection but which also causes fewer side‐effects than CNI.

See all (5)

PubMed Health Blog...

read all...